تجاوز إلى المحتوى الرئيسي
من
المنتج التاريخ معلومات السلامة المرفقات
Xeljanz® (Tofacitinib) 2019-05-06

Increased risk of pulmonary embolism and overall mortality with higher dose of XELJANZ (tofacitinib) for rheumatoid arthritis.

Jectin-12® (Cyanocobalamin) 2019-05-06

Cyanocobalamin and the risk of medication error.

Genvoya ® (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide) 2019-04-29

Increased risk of treatment failure and increased risk of mother-to-child transmission of HIV infection due to lower exposure of elvitegravir and cobicistat during the second and third trimesters of pregnancy.

Dapagliflozin 2019-04-15

Risk of Fournier’s gangrene (necrotising fasciitis of the perineum) with Sodium-glucose-Co-Transporter 2 inhibitors (SGLT2i).

Adenuric® (Febuxostat) 2019-04-04

Febuxostat (adenuric®): Higher rate of cardiovascular death in gout patients with established cardiovascular disease.

Belimumab 2019-03-25

Benlysta (Belimumab) and Risk of serious Depression and/ or Suicidal ideation or Behavior or self-injury.

Atezolizumab 2019-02-26

TECENTRIQ® (atezolizumab): A New Important Identified Risk: Immune-related Myositis.

Canagliflozin 2019-02-04

Risk of Fournier´s gangrene (necrotising fasciitis of the perineum) with Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i).

Pembrolizumab 2019-01-22

Keytruda (pembrolizumab): Restriction of indication for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy.

Empagliflozin 2018-12-16

Direct Healthcare Professional Communication on the association of Sodium-Glucose-Co-Transporter 2 inhibitors (SGLT2i) with Risk of Fournier´s gangrene (necrotising fasciitis of the perineum).

عرض 41 - 50 من 105